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ABSTRACT
The coronavirus disease 2019 (COVID-19) global pandemic has resulted in diversion of healthcare resources to the
management of patients infected with SARS-CoV-2 virus. Elective interventions and surgical procedures in most coun-
tries have been postponed and operating room resources have been diverted to manage the pandemic. The Venous and
Lymphatic Triage and Acuity Scale was developed to provide an international standard to rationalise and harmonise the
management of patients with venous and lymphatic disorders or vascular anomalies. Triage urgency was determined
based on clinical assessment of urgency with which a patient would require medical treatment or surgical intervention.
Clinical conditions were classified into six categories of: (1) venous thromboembolism (VTE), (2) chronic venous disease, (3)
vascular anomalies, (4) venous trauma, (5) venous compression and (6) lymphatic disease. Triage urgency was categorised
into four groups and individual conditions were allocated to each class of triage. These included (1) medical emergencies
(requiring immediate attendance), example massive pulmonary embolism; (2) urgent (to be seen as soon as possible),
example deep vein thrombosis; (3) semiurgent (to be attended to within 30-90 days), example highly symptomatic
chronic venous disease, and (4) discretionary/nonurgent- (to be seen within 6-12 months), example chronic lymphoe-
dema. Venous and Lymphatic Triage and Acuity Scale aims to standardise the triage of patients with venous and
lymphatic disease or vascular anomalies by providing an international consensus-based classification of clinical cate-
gories and triage urgency. The scale may be used during pandemics such as the current COVID-19 crisis but may also be
used as a general framework to classify urgency of the listed conditions. (J Vasc Surg: Venous and Lym Dis 2020;8:706-10.)
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The global coronavirus disease 2019 (COVID-19)
pandemic has resulted in diversion of healthcare re-
sources including workforce, critical supplies, emer-
gency and intensive care unit (ICU) facilities and
personal protective equipment (PPE) to the manage-
ment of patients infected with SARS-CoV-2 virus.
Elective interventions and surgical procedures in
most countries have been postponed and operating
room resources have been diverted to manage the
pandemic.1 Limitations on direct personal contact
and physical (social) distancing have influenced access
to care and how it is provided. Patients with venous
and lymphatic disorders or vascular anomalies
continue to need expert care within current public
health constraints. In addition, there is growing evi-
dence that COVID-19 may predispose patients to both
arterial and venous thromboembolic (VTE) disease
and extensive coagulopathies further complicating
the prognosis of the affected patients.2-4 To facilitate
triage in this demanding setting we recommend the
use of a standardised scale to rationalise and harmo-
nise the management of these patients during this
difficult period.
AIMS
The Venous and Lymphatic Triage and Acuity Scale
(VELTAS) was developed to provide an international stan-
dard for the triage of patients with venous and lymphatic
disorders or vascular anomalies. VELTAS aims to improve
patient safety and increase triage reliability by providing
a standardised framework for the management of these
conditions.METHODS
Stratification of triage urgency. Triage urgency is
defined as the clinical assessment of urgency with which
a patient would require medical treatment or surgical
intervention.5 The principle for triage and prioritisation
for admission for medical treatment or procedural
interventions and surgery is based on the natural history
and expected clinical outcomes of the condition, the
rate of progression and deterioration, and the compli-
cations that may arise should treatment be delayed or
withheld.6 The rationale for triage is ‘to do the greatest
good for the greatest number’.7
Various models and strategies for stratifying urgency
during the COVID-19 pandemic have been proposed.8-10
In this document, the appropriate timeline to attend to
individual conditions was determined by an interna-
tional panel of vascular experts.
The consensus process. The project was initiated by the
International Union of Phlebology (UIP) in conjunction
with the Australasian College of Phlebology. Thedocument was written by the primary authors and further
reviewed and developed by the co-editors, based on
appraisal of current evidence in the literature published in
print or online through April 2020. When evidence was
lacking or limited, consensus was developed. The docu-
ment was shared with an international expert panel of
phlebologists and vascular specialists representing the
endorsing societies and further topics and recommen-
dations were included and the final document formu-
lated. Consensus on triage and acuity was reached when
a recommendation was unanimously supported by all
authors. In case of any dissenting opinion multiple at-
tempts were made to modify the recommendation. At
the end of the consensus process, all participating authors
approved the final version of the document and agreed to
be accountable for all aspects of the work.
Utility and target audience. The scale is designed pri-
marily for phlebologists and vascular specialists but will
be also useful for primary physicians and general practi-
tioners, referring doctors, emergency specialists and
other healthcare professionals and health policymakers.
VELTAS will be especially relevant during pandemics
such as the current COVID-19 crisis but may also be
used as a general framework to classify urgency of the
listed conditions.
Scope. The scale includes a comprehensive range of
conditions seen by phlebologists and other vascular spe-
cialists involved in the management of patients with
venous and lymphatic disorders or vascular anomalies
as defined by the UIP curriculum.11
Recommendations. Clinical conditions within the scope
ofphlebologywereclassified intosixcategoriesof (1)VTE, (2)
chronic venous disease (CVD), (3) vascular anomalies, (4)
venous trauma, (5) venous compression and (6) lymphatic
disease. Triage urgency in each clinical categorywas classi-
fied into four groups of (1)medical emergencies, (2) urgent,
(3) semiurgent and (4) discretionary/nonurgent. Individual
conditions in each clinical category were allocated to a
class of triage by the expert panel (Table).
Adaptation to pandemic circumstances. We recognise
that clinical practice and expectations need to be adapt-
ed in times of regional or global crisis. Under pandemic
circumstances patients are encouraged to continue to
consult their general practitioners and primary care
physicians via appropriate means such as tele-health fa-
cilities to initiate management and to obtain a referral to
phlebologists or other vascular specialists when necessary.
During the pandemic, tele-health facilities should be used
by treating specialists as much as possible to address
patients concerns and provide advice on treatment op-
tions. Medical emergencies should continue to be triaged
by emergency services where available.








Acute Immediate VTE  Massive PE with or without DVT
 Acute iliofemoral DVT with phlegmasia9 or
sepsis
 Acute ASVT with phlegmasia
 Acute central vein thrombosis with superior
vena cava syndrome
 Acute MVT with peritonitis
 Acute paradoxical embolism and stroke10
 Venous gangrene
Life-threatening CVD  Life-threatening blood loss10 from a
bleeding varix







 Kasabach-Merrit syndrome with severe
coagulopathy
 Severe cardiac failure secondary to AVM
Venous trauma  Life or limb-threatening venous trauma10
Lymphatic
disease
 Acute septicaemia or uncontrolled
lymphangitis or secondary infection
Category 1 Acute As soon as
possible
VTE  PE,10 DVT, ASVT, MVT or extensive proximal
SVTd 12,13
 DVT requiring IVC filter placement14
 Acute central vein thrombosis with or
without haemodialysis access






CVD  Temporarily controlled bleeding varices
 Infected wounds and ulcers with risk of
septicaemia









 Acute complications including infection,
bleeding and thrombosis
 Cardiac failure secondary to AVM
 Vascular malignancies
Venous trauma  Nonlife or limb-threatening venous trauma
Lymphatic
disease
 Lymphoedema with extensive
lymphangitis or secondary cellulitis and risk
of septicaemia
Category 2 May be chronic or
new onset
Within 30-90 days VTE  Symptomatic nonextensive SVTd





ment by the refer-
ring doctor
CVD  CEAP15 C3eC6e
 Highly symptomatic CVD (irrespective of
CEAP classification)e








 Complex or extensive vascular tumours and
malformations
 LIC within a vascular malformation or
tumour












 Chronic lymphoedema with secondary
infection or cutaneous changes






Indications for medical treatmenta or
interventionb
Category 3 Chronic Within
6-12 months








ment by the refer-
ring doctor
CVD  CEAP C0SeC2e
 Mildly symptomatic pelvic venous
insufficiency, varicocelesf

















 Chronic lymphoedema or lipoedema
ASVT, Acute axillary subclavian vein thrombosis; AVM, arteriovenous malformation; CEAP, Clinical, Etiological, Anatomical, Pathophysiology classifi-
cation; CVD, chronic venous disease; DVT, deep vein thrombosis; IVC, inferior vena cava; LIC, localised intravascular coagulopathy; MVT, mesenteric vein
thrombosis; PE, pulmonary embolism; SVT, superficial vein thrombosis; TOS, thoracic outlet syndrome; VTE, venous thromboembolism.
aMedical treatment started at admission may be continued in an outpatient setting.
bIntervention can be performed in a nonhospital ambulatory or outpatient setting.
cVascular anomalies incorporate two broad categories of vascular tumours such as haemangiomas and vascular malformations. The latter further
includes venous (VM), arteriovenous (AVM), lymphatic (LM), capillary (CM), combined, complex and syndromic malformations in adults and children.
dExtensive SVT is defined as above-knee great saphenous SVT $5 cm long whilst nonextensive SVT is defined as nonsaphenous SVT, below-knee
saphenous SVT or above-knee saphenous SVT <5 cm in length.
eDuring pandemic circumstances, CVD should be initially managed in the community with a trial of medical treatments including compression
therapy if appropriate; advice from vascular specialists to be obtained using tele-health technology where available.
f This indication excludes asymptomatic patients from triage categories and includes symptomatic patients only, as there is no current indication to
intervene for asymptomatic MayeThurner syndrome, other venous compression syndromes or asymptomatic pelvic venous insufficiency.
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(1) This document should be used as a general guide-
line applicable to both hospital and nonhospital
ambulatory settings.
(2) Decisions regarding clinical urgency need to
consider the patients’ individual circumstances
and loco-regional variations in the clinical practice
of medicine, hospital policies and government-
enforced guidelines and directives.
(3) In developing VELTAS we recognise and acknowl-
edge that some conditions:
(i) can be managed differently;
(ii) can be managed completely or in part by a
variety of other healthcare providers;
(iii) are less urgent and hence can be managed
more conservatively;
(iv) when chronic, can be safely delayed for defini-
tive procedural interventions; and
(v) must be dealt with just as promptly despite the
pandemic.
(4) The scale does not replace the treating physician’s
clinical judgement of acuity and severity and the
requirement for intervention as applicable in
different models of healthcare.
(5) The specified times for attendance indicate the
ideal time frames within which patients should
be seen and attended to. Such ideal timelines
may be influenced by other factors such as avail-
ability of resources, other competing national or
regional requirements for critical supplies andPPE, and national, regional, local and individual
hospital admission policies.
(6) This document should not be used to delay or
deny treatment of less urgent cases, deny or mini-
mise reimbursement for services provided, or limit
access to healthcare when resources are not
limited, and such care does not present a risk to
patients or health care workers.CONCLUSIONS
VELTAS is a triage and acuity scale dedicated to the
care of patients with acute and chronic venous and
lymphatic disorders or vascular anomalies. The scale
aims to standardise the triage of this group of patients
by providing a consensus-based classification of clinical
categories and triage urgency.
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